Invention Grant
US08354377B2 Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH) in a selected subpopulation of ICH patients
有权
在选定的ICH患者亚群中，使用因子VIIa或VIIa因子来预防或减弱出血发生和/或颅内出血（ICH）后的水肿发生
- Patent Title: Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH) in a selected subpopulation of ICH patients
- Patent Title (中): 在选定的ICH患者亚群中，使用因子VIIa或VIIa因子来预防或减弱出血发生和/或颅内出血（ICH）后的水肿发生
-
Application No.: US12812684Application Date: 2009-01-16
-
Publication No.: US08354377B2Publication Date: 2013-01-15
- Inventor: Brett Skolnick , Nikolai Constantin Brun , Kamilla Begtrup
- Applicant: Brett Skolnick , Nikolai Constantin Brun , Kamilla Begtrup
- Applicant Address: CH Zurich
- Assignee: Novo Nordisk Health Care AG
- Current Assignee: Novo Nordisk Health Care AG
- Current Assignee Address: CH Zurich
- Agent Michael J. Brignati
- Priority: EP08100633 20080118; EP08100916 20080125
- International Application: PCT/EP2009/050488 WO 20090116
- International Announcement: WO2009/090240 WO 20090723
- Main IPC: A61K38/00
- IPC: A61K38/00
Abstract:
The invention relates to a method for preventing or attenuating one or more complications of intracerebral haemorrhage (ICH), the method comprising: (i) selecting an ICH patient who exhibits one or more of the following characteristics: age≦70, baseline ICH volume≦60 mL, baseline IVH volume≦5 mL, and elapsed time since onset of symptoms of less than about 2.5 hours; and (ii) administering to said patient in need thereof an effective amount of a first coagulation agent comprising Factor VIIa or a Factor VIIa equivalent.
Public/Granted literature
Information query
IPC分类:
